DOCSLIB.ORG

SPECIFIC DRUGS IDENTIFIED AS PSYCHIATRIC MEDICATIONS Appendix D

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SPECIFIC DRUGS IDENTIFIED AS PSYCHIATRIC MEDICATIONS Appendix D APPENDIX D: SPECIFIC DRUGS IDENTIFIED AS PSYCHIATRIC MEDICATIONS Appendix D. Pharmaceutical Groups Used to Define Psychiatric Medications Multum_Category Category_Name Multum Drug_Name 68 Barbiturates d00171 Amobarbitol 68 Barbiturates d00335 Pentobarbital 68 Barbiturates d00340 Phenobarbital 68 Barbiturates d00368 Secobarbital 68 Barbiturates d00919 Mephobarbital 68 Barbiturates d00923 Butabarbital 68 Barbiturates d03061 Butalbital 68 Barbiturates d04005 Amobarbital-Secobarbital 69 Benzodiazepines d00040 Oxazepam 69 Benzodiazepines d00148 Diazepam 69 Benzodiazepines d00149 Lorazepam 69 Benzodiazepines d00168 alprazolam 69 Benzodiazepines d00189 Chlordiazepoxide 69 Benzodiazepines d00197 Clonazepam 69 Benzodiazepines d00198 Clorazepate 69 Benzodiazepines d00238 Flurazepam 69 Benzodiazepines d00301 Midazolam 69 Benzodiazepines d00384 Temazepam 69 Benzodiazepines d00397 Triazolam 69 Benzodiazepines d00904 Halazepam 69 Benzodiazepines d00915 Estazolam 69 Benzodiazepines d00917 Quazepam 70 Miscellaneous Anxiolytics, Sedatives and Hypnotics d00147 Chloral Hydrate 70 Miscellaneous Anxiolytics, Sedatives and Hypnotics d00182 Buspirone 70 Miscellaneous Anxiolytics, Sedatives and Hypnotics d00212 Diphenhydramine 70 Miscellaneous Anxiolytics, Sedatives and Hypnotics d00217 Doxepin 70 Miscellaneous Anxiolytics, Sedatives and Hypnotics d00226 Ethchlorvynol 70 Miscellaneous Anxiolytics, Sedatives and Hypnotics d00288 Meprobamate 70 Miscellaneous Anxiolytics, Sedatives and Hypnotics d00782 Pyrilamine 70 Miscellaneous Anxiolytics, Sedatives and Hypnotics d00907 Hydroxyzine 70 Miscellaneous Anxiolytics, Sedatives and Hypnotics d00909 Chlormezanone 70 Miscellaneous Anxiolytics, Sedatives and Hypnotics d00910 Zolpidem 70 Miscellaneous Anxiolytics, Sedatives and Hypnotics d00911 Paraldehyde 70 Miscellaneous Anxiolytics, Sedatives and Hypnotics d00912 Acetylcarbromal 70 Miscellaneous Anxiolytics, Sedatives and Hypnotics d00914 Propiomazine 70 Miscellaneous Anxiolytics, Sedatives and Hypnotics d03068 Dichloralphenazone 70 Miscellaneous Anxiolytics, Sedatives and Hypnotics d03154 Doxylamine 70 Miscellaneous Anxiolytics, Sedatives and Hypnotics d04452 Zaleplon 70 Miscellaneous Anxiolytics, Sedatives and Hypnotics d04505 Dexmedetomidine 71 CNS Stimulants d00801 Caffeine 71 CNS Stimulants d00802 Doxapram 71 CNS Stimulants d00803 Amphetamine 71 CNS Stimulants d00804 Dextroamphetamine 71 CNS Stimulants d00805 Methamphetamine 71 CNS Stimulants d00806 Phentermine 71 CNS Stimulants d00807 Benzphetamine 71 CNS Stimulants d00809 Phendimetrazine Appendix D. Pharmaceutical Groups Used to Define Psychiatric Medications Multum_Category Category_Name Multum Drug_Name 71 CNS Stimulants d00810 Diethylpropion 71 CNS Stimulants d00811 Mazindol 71 CNS Stimulants d00812 Fenfluramine 71 CNS Stimulants d00900 Methylphenidate 71 CNS Stimulants d00901 Pemoline 71 CNS Stimulants d04035 Amphetamine-DextroAmphetamine 71 CNS Stimulants d04036 Caffeine-Sodium Benzoate 71 CNS Stimulants d04378 Modafinil 71 CNS Stimulants d04777 Dexmethylphenidate 76 Miscellaneous Antidepressants d00181 Bupropion 76 Miscellaneous Antidepressants d00395 Trazodone 76 Miscellaneous Antidepressants d00877 Maprotiline 76 Miscellaneous Antidepressants d03181 Venlafaxine 76 Miscellaneous Antidepressants d03808 Nefazodone 76 Miscellaneous Antidepressants d04025 Mirtazapine 76 Miscellaneous Antidepressants d04408 St. John's Wort 76 Miscellaneous Antidepressants d04726 5-Hydroxytryptophan 77 Miscellaneous Antipsychotic agents d00027 Haloperidol 77 Miscellaneous Antipsychotic agents d00061 Lithium 77 Miscellaneous Antipsychotic agents d00199 Clozapine 77 Miscellaneous Antipsychotic agents d00896 Molindone 77 Miscellaneous Antipsychotic agents d00897 Loxapine 77 Miscellaneous Antipsychotic agents d00898 Pimozide 77 Miscellaneous Antipsychotic agents d03180 Risperidone 77 Miscellaneous Antipsychotic agents d04050 Olanzapine 77 Miscellaneous Antipsychotic agents d04220 Quetiapine 77 Miscellaneous Antipsychotic agents d04747 Ziprasidone 79 Psychotherapeutic Combinations d03462 Amitriptyline-Chlordiazepoxide 79 Psychotherapeutic Combinations d03463 Amitriptyline-Perphenazine 80 Miscellaneous Central Nervous system agents d00902 Ergoloid Mesylates 80 Miscellaneous Central Nervous system agents d03176 Tacrine 80 Miscellaneous Central Nervous system agents d04031 Pilocarpine 80 Miscellaneous Central Nervous system agents d04099 Donepezil 80 Miscellaneous Central Nervous system agents d04512 Cevimeline 80 Miscellaneous Central Nervous system agents d04537 Rivastigmine 80 Miscellaneous Central Nervous system agents d04750 Galantamine 208 SSRI Antidepressants d00236 Fluoxetine 208 SSRI Antidepressants d00880 Sertraline 208 SSRI Antidepressants d03157 Paxil 208 SSRI Antidepressants d03804 Paroxetine 208 SSRI Antidepressants d04332 Citalopram 209 Tricyclic Antidepressants d00144 Nortriptyline 209 Tricyclic Antidepressants d00145 Desipramine 209 Tricyclic Antidepressants d00146 Amitriptyline 209 Tricyclic Antidepressants d00217 Doxepin 209 Tricyclic Antidepressants d00259 Imipramine 209 Tricyclic Antidepressants d00873 Trimipramine Appendix D. Pharmaceutical Groups Used to Define Psychiatric Medications Multum_Category Category_Name Multum Drug_Name 209 Tricyclic Antidepressants d00874 Amoxapine 209 Tricyclic Antidepressants d00875 Protriptyline 209 Tricyclic Antidepressants d00876 Clomipramine 210 Phenothiazine AntiPsychotics d00064 Chlorpromazine 210 Phenothiazine AntiPsychotics d00237 Fluphenazine 210 Phenothiazine AntiPsychotics d00355 Prochlorperazine 210 Phenothiazine AntiPsychotics d00356 Promazine 210 Phenothiazine AntiPsychotics d00389 Thioridazine 210 Phenothiazine AntiPsychotics d00855 Perphenazine 210 Phenothiazine AntiPsychotics d00889 Mesoridazine 210 Phenothiazine AntiPsychotics d00890 Trifluoperazine 210 Phenothiazine AntiPsychotics d03152 Triflupromazine 242 Psychotherapeutic agents only Nitroglycerine was coded in this category, and we decided not to include this as a Psychotropic medicine 249 Antidepressants only Nitroglycerine was coded in this category, and we decided not to include this as a Psychotropic medicine 250 Monoamine oxidase inhibitors d00882 Isocarboxazid 250 Monoamine oxidase inhibitors d00883 Phenelzine 250 Monoamine oxidase inhibitors d00884 Tranylcypromine 251 Antipsychotics only Nitroglycerine was coded in this category, and we decided not to include this as a Psychotropic medicine.
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • An Approach to the Patient with a Dry Mouth
    MedicineToday 2014; 15(4): 30-37 PEER REVIEWED FEATURE 2 CPD POINTS An approach to the patient with a dry mouth Key points • The subjective complaint of ELHAM AFLAKI MD; TAHEREH ERFANI MD; NICHOLAS MANOLIOS MB BS(Hons), PhD, MD, FRACP, FRCPA; xerostomia needs to be MARK SCHIFTER FFD, RCSI(Oral Med), FRACDS(Oral Med) differentiated from true salivary hypofunction. Dry mouth is a common and disabling problem. After exclusion of treatable • Salivary hypofunction can significantly reduce quality causes, treatment is symptomatic to prevent the consequences of salivary of life through its adverse hypofunction, such as tooth decay and infection of the oral mucosa. effects on taste, mastication, swallowing, cleansing of the erostomia, or the subjective feeling of neuropathic-induced orofacial dysaesthesia) mouth, killing of microbes a dry mouth, is a common complaint. and psychological and psychiatric disorders, and speech. It is often a consequence of salivary such as anxiety and depression. • Salivary hypofunction is a hypofunction (hyposalivation), in substantive risk factor for X which there is objective evidence of reduced NORMAL SALIVA PRODUCTION dental caries, oral mucosal salivary output or qualitative changes in saliva. Under normal physiological conditions, the disease and infection, Typically, patients complain of oral dryness salivary glands produce 1000 to 1500 mL of particularly oral candidiasis. only when salivary secretion is reduced by more saliva daily as an ultrafiltrate from the circu- • Patients should be than half.1 As saliva has a crucial role in taste lating plasma. Therefore, simple dehydration investigated for contributory perception, mastication, swallowing, cleansing reduces saliva production. The parotid glands and underlying causes, of the mouth, killing of microbes and speech, are the major source of serous saliva (60 to 65% which include drugs and abnormalities in saliva production can signif- of total saliva volume), producing the stimu- rheumatological diseases.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Chlormezanone Item No. 25716 CAS Registry No.: 80-77-3 Formal Name: 2-(4-chlorophenyl)tetrahydro-3-methyl-4H- O 1,3-thiazin-4-one, 1,1-dioxide Synonyms: (±)-Chlormezanone, NSC 169108 N MF: C11H12ClNO3S FW: 273.7 Purity: ≥98% S OO UV/Vis.: λmax: 228 nm Supplied as: A crystalline solid Cl Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Chlormezanone is supplied as a crystalline solid. A stock solution may be made by dissolving the chlormezanone in the solvent of choice. Chlormezanone is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of chlormezanone in these solvents is approximately 2, 20, and 10 mg/ml, respectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of chlormezanone can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of chlormezanone in PBS, pH 7.2, is approximately 0.1 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description Chlormezanone is a centrally acting muscle relaxant.1 It induces paralysis in mice, guinea pigs, dogs, cats, and monkeys (EC50s = 133, <200, 100-250, 50, and 50 mg/kg, respectively). Chlormezanone increases ataxia induced by pentobarbital and alcohol in mice and blocks the crossed extensor reflex of the spine without affecting the knee-jerk reflex in cats.
    [Show full text]
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
    [Show full text]
  • Anthem Blue Cross Drug Formulary
    Erythromycin/Sulfisoxazole (generic) INTRODUCTION Penicillins ...................................................................... Anthem Blue Cross uses a formulary Amoxicillin (generic) (preferred list of drugs) to help your doctor Amoxicillin/Clavulanate (generic/Augmentin make prescribing decisions. This list of drugs chew/XR) is updated quarterly, by a committee Ampicillin (generic) consisting of doctors and pharmacists, so that Dicloxacillin (generic) the list includes drugs that are safe and Penicillin (generic) effective in the treatment of diseases. If you Quinolones ..................................................................... have any questions about the accessibility of Ciprofloxacin/XR (generic) your medication, please call the phone number Levofloxacin (Levaquin) listed on the back of your Anthem Blue Cross Sulfonamides ................................................................ member identification card. Erythromycin/Sulfisoxazole (generic) In most cases, if your physician has Sulfamethoxazole/Trimethoprim (generic) determined that it is medically necessary for Sulfisoxazole (generic) you to receive a brand name drug or a drug Tetracyclines .................................................................. that is not on our list, your physician may Doxycycline hyclate (generic) indicate “Dispense as Written” or “Do Not Minocycline (generic) Substitute” on your prescription to ensure Tetracycline (generic) access to the medication through our network ANTIFUNGAL AGENTS (ORAL) _________________ of community
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0108602 A1 Chu Et Al
    US 2003O1086O2A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0108602 A1 Chu et al. (43) Pub. Date: Jun. 12, 2003 (54) TABLETS AND METHODS FOR MODIFIED (22) Filed: Jul. 8, 2002 RELEASE OF HYDROPHILIC AND OTHER ACTIVE AGENTS Related U.S. Application Data (75) Inventors: James Shunnan Chu, Palo Alto, CA (63) Continuation of application No. 09/599,102, filed on (US); Yisong Yang, Sunnyvale, CA May 19, 2000, now Pat. No. 6,419,954. (US); Joseph A. Fix, Half Moon Bay, CA (US) Publication Classification Correspondence Address: (51) Int. Cl. ............................................... A61K 9/20 TOWNSEND AND TOWNSEND AND CREW, (52) U.S. Cl. .............................................................. 424/465 LLP TWO EMBARCADERO CENTER EIGHTH FLOOR (57) ABSTRACT SAN FRANCISCO, CA 94111-3834 (US) (73) Assignee: Yamanouchi Pharma Technologies, The invention provides a tablet and methods for making the Inc., Palo Alto, CA (US) tablet comprising a gel-forming material and at least one particle comprising an active agent in contact with a coating (21) Appl. No.: 10/191,979 material to modify release of the active agent. Patent Application Publication Jun. 12, 2003 Sheet 1 of 11 US 2003/0108602 A1 (O) N 3(O) 2(O) A/G /A Patent Application Publication Jun. 12, 2003. Sheet 2 of 11 US 2003/0108602 A1 O / O2 OOO OO O Q(SO39 O KC O () i88. OOO OO Okk (ki (k) <k. SJS19O OO <! o O OSS) O O 33 kg) O<< 3k 32 "ooO O & : A/6, 2O Patent Application Publication Jun. 12, 2003 Sheet 3 of 11 US 2003/0108602 A1 Active POWCer (Cevimeline HCI) Formulation Parameters -Pretreatment of Active -Binder: Solid or Solution Binder -% Content of Binder (HPC or PEO/PEG) -Amount of Water Process Parameters -Equipment Selection -Spray Technique Pelletization -Product Temperature (Granulation) -Drying Procedure Process -Milling Technique -High Shear G -Fluid-Bed G In-Process Tests -Yield Active Pellet/Granules -Physical Characteristics -ASSay FIG.
    [Show full text]
  • Cochrane Library
    Cochrane Library Cochrane Database of Systematic Reviews Sedation of children undergoing dental treatment (Review) Ashley PF, Chaudhary M, Lourenço-Matharu L Ashley PF, Chaudhary M, Lourenço-Matharu L. Sedation of children undergoing dental treatment. Cochrane Database of Systematic Reviews 2018, Issue 12. Art. No.: CD003877. DOI: 10.1002/14651858.CD003877.pub5. www.cochranelibrary.com Sedation of children undergoing dental treatment (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Cochrane Trusted evidence. Informed decisions. Library Better health. Cochrane Database of Systematic Reviews T A B L E O F C O N T E N T S HEADER......................................................................................................................................................................................................... 1 ABSTRACT..................................................................................................................................................................................................... 1 PLAIN LANGUAGE SUMMARY....................................................................................................................................................................... 2 SUMMARY OF FINDINGS.............................................................................................................................................................................. 3 BACKGROUND.............................................................................................................................................................................................
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • Potentially Harmful Drugs in the Elderly: Beers List
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− March 2019 ~ Resource #350301 Potentially Harmful Drugs in the Elderly: Beers List In 1991, Dr. Mark Beers and colleagues published a methods paper describing the development of a consensus list of medicines considered to be inappropriate for long-term care facility residents.12 The “Beers list” is now in its sixth permutation.1 It is intended for use by clinicians in outpatient as well as inpatient settings (but not hospice or palliative care) to improve the care of patients 65 years of age and older.1 It includes medications that should generally be avoided in all elderly, used with caution, or used with caution or avoided in certain elderly.1 There is also a list of potentially harmful drug-drug interactions in seniors, as well as a list of medications that may need to be avoided or have their dosage reduced based on renal function.1 This information is not comprehensive; medications and interactions were chosen for inclusion based on potential harm in relation to benefit in the elderly, and availability of alternatives with a more favorable risk/benefit ratio.1 The criteria no longer address drugs to avoid in patients with seizures or insomnia because these concerns are not unique to the elderly.1 Another notable deletion is H2 blockers as a concern in dementia; evidence of cognitive impairment is weak, and long-term PPIs pose risks.1 Glimepiride has been added as a drug to avoid. Some drugs have been added with cautions (dextromethorphan/quinidine, trimethoprim/sulfamethoxazole), and some have had cautions added (rivaroxaban, tramadol, SNRIs).
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Acetaminophen, Isometheptene, and Dichloralphenazone
    PATIENT & CAREGIVER EDUCATION Acetaminophen, Isometheptene, and Dichloralphenazone This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Nodolor [DSC] Warning This drug has acetaminophen in it. Liver problems have happened with the use of acetaminophen. Sometimes, this has led to a liver transplant or death. Most of the time, liver problems happened in people taking more than 4,000 mg (milligrams) of acetaminophen in a day. People were also often taking more than 1 drug that had acetaminophen. Avoid drinking alcohol while taking this drug. What is this drug used for? It is used to treat headaches. Acetaminophen, Isometheptene, and Dichloralphenazone 1/8 What do I need to tell my doctor BEFORE I take this drug? If you have an allergy to acetaminophen, isometheptene, dichloralphenazone, or any other part of this drug. If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have any of these health problems: Glaucoma, heart disease, high blood pressure, liver disease, or poor kidney function. If you have blood vessel problems, including in the heart or brain. If you have had a recent heart attack or stroke. If you have taken certain drugs for depression or Parkinson’s disease in the last 14 days. This includes isocarboxazid, phenelzine, tranylcypromine, selegiline, or rasagiline. Very high blood pressure may happen.
    [Show full text]
  • Randomized Controlled Pilot Trial of Cabergoline, Hydergine and Levodopa/Carbidopa: Los Angeles Cocaine Rapid Efficacy Screening
    Blackwell Science, LtdOxford, UKADDAddiction1359-6357© 2005 Society for the Study of Addiction 100•••• Original Article Cabergoline, hydergine, levodopa/carbidopa Steven Shoptaw et al. RESEARCH REPORT Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST) Steven Shoptaw1, Donnie W. Watson2, Chris Reiber1, Richard A. Rawson1, Margaret A. Montgomery3, Maria D. Majewska3 & Walter Ling1 UCLA Integrated Substance Abuse Programs, Los Angeles, CA1 , Friends Research Institute, Inc., Los Angeles, CA2 and National Institute on Drug Abuse, Division of Treatment Research and Development, Bethesda, MD, USA3 Correspondence to: ABSTRACT Steven Shoptaw PhD UCLA/Integrated Substance Abuse Programs Aim This study tested three dopaminergic medications against a common 11075 Santa Monica Blvd unmatched placebo condition: hydergine 1 mg three times daily (n = 15); Suite 200 levodopa/carbidopa 25/100 mg three times daily (n = 15); cabergoline 0.5 mg Los Angeles per week (n = 15); and placebo three times daily (n = 15) as potential pharma- CA 90025 USA cotherapies for cocaine dependence. E-mail: [email protected] Design The four-parallel group, Cocaine Rapid Efficacy Screening Trial (CREST) design featured a 2-week baseline period followed by randomization to an 8-week medication condition that included 1 hour per week of cognitive RESEARCH REPORT behavioral drug counseling. A safety evaluation was conducted 4 weeks after termination. Measures Outcomes included cocaine metabolites measured in urine, reten- tion and self-reports for drug use, cocaine craving, clinical improvement, mood and HIV risk behaviors. Results Participants assigned to receive cabergoline provided more urine sam- ples negative for cocaine metabolites (42.4%) than those assigned to receive pla- cebo (25.0%), a statistically significant difference after controlling for baseline differences in self-reported cocaine use (F = 2.95, df = 3; P = 0.05).
    [Show full text]